Back to Results
First PageMeta Content
Monoclonal antibodies / Immunology / Humanized antibody / Retrovirus / ERVWE1 / Biology / Molecular biology / Endogenous retroviruses


GENEURO INNOVATION SAS One line pitch: GeNeuro develops biotechnology treatments for disorders associated with endogenous retrovirus expression and presenting high unmet medical needs Market Analysis:
Add to Reading List

Document Date: 2014-07-25 09:30:19

Open Document

File Size: 182,24 KB

Share Result on Facebook

City

Lyon / /

Company

Curtin Francois / /

Country

France / United States / /

Currency

USD / /

/

IndustryTerm

other MS therapeutics / biotechnology treatments / /

MedicalCondition

autoimmune disorders / burn / multiple sclerosis / schizophrenia / disease / chronic forms / MS / inflammatory crises / diabetes / inflammatory / disorders / /

MedicalTreatment

immunotherapy / /

Organization

Institut Mérieux / /

Person

Perron Hervé / Eclosion / Anne-Marie Graffin / /

Position

CEO / CSO Lang Alois CDO Guichard Christophe CFO / /

ProvinceOrState

Mississippi / /

Technology

antibodies / biotechnology / /

URL

geneuro.com / /

SocialTag